Finding Solutions to Decades of Cancer Drug Shortages in Spotlight at Annual Meeting

June 4, 2024

The American Society of Clinical Oncology (ASCO) hosted a panel discussion focused on finding solutions to the crisis of cancer drug shortages at the 2024 ASCO Annual Meeting. The session, “Solving Decades of Drug Shortages in Oncology: What, Who, and When?,” featured experts to review potential market/economic factors that can improve resiliency in the sterile injectable drug market and potential policy changes to help mitigate future shortages.

The panel, moderated by the Society’s Chief Medical Officer, Julie Gralow, MD, FACP, FASCO, included:

  • Robert Califf, MD, Commissioner, Food and Drug Administration
  • Marta Wosinska, PhD, Senior Fellow, The Brookings Institution
  • Alex Oshmyansky, MD, PhD, Co-Founder and CEO, Mark Cuban Cost Plus Drug Company
  • Allan Coukell, BScPharm, Chief Government Affairs and Public Policy Officer, Civica Rx
  • Michael Sargent, Senior Director, Policy, Association for Accessible Medicines

The session touched on mitigation strategies, such as increasing supply chain visibility, and ways to better monitor and identify impending shortages and drugs at high-risk of shortage, while avoiding panic buying. Most of the discussion, however, focused on preventing cancer drug shortages by addressing key economic factors in the generic drug market to improve its resiliency.

Watch a recording of the full session.

ASCO has a long and robust history of working to end cancer drug shortages. Visit asco.org/impossiblechoices for the latest or contact your lawmakers using the ACT Network. Clinical guidance and updates on shortages are also available on asco.org/drug-shortages.

Bookmark ASCO in Action for updates on cancer drug shortages, as well as news, advocacy, and analysis on cancer policy.